Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo. [electronic resource]
Producer: 20181217Description: 13-26 p. digitalISSN:- 1873-2968
- Adolescent
- Adult
- Aged
- Antineoplastic Agents -- pharmacology
- Cell Line, Tumor
- Cell Survival -- drug effects
- Child
- Child, Preschool
- Drug Delivery Systems
- Extracellular Signal-Regulated MAP Kinases -- genetics
- Female
- Gene Expression Regulation -- drug effects
- Humans
- Leukemia, Myeloid, Acute -- drug therapy
- Male
- Metabolic Networks and Pathways -- drug effects
- Middle Aged
- Phosphatidylinositol 3-Kinases -- genetics
- Proto-Oncogene Proteins c-bcl-2 -- genetics
- TOR Serine-Threonine Kinases -- genetics
- Up-Regulation
- Young Adult
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.